会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Ophtalmic compound with extended dwell time on the eye
    • 眼部化合物在眼睛上延长停留时间
    • US06599944B1
    • 2003-07-29
    • US09171344
    • 2000-05-19
    • Gunther BellmannGudrun Claus-Herz
    • Gunther BellmannGudrun Claus-Herz
    • A61K3114
    • A61K9/0048A61K31/07
    • Ophthalmic composition with prolonged residence time on the eye, in particular in the form of a gel which can be administered as drops, of an ointment or the like, containing a free-flowing vehicle with increased viscosity and a preservative, and, where appropriate, one or more active ingredients and conventional additives such as tonicity agents, substances to adjust the pH etc. The preservative is essentially formed according to the invention by a benzyllauryldimethylammonium salt. The invention furthermore relates to the use of a benzyllauryldimethylammonium salt as preservative for producing ophthalmic compositions intended for repeated use over lengthy periods and/or formulated for a lengthy residence time on the eye after each use, whereby irritation and/or damage to the tissue of the eye are avoided.
    • 具有延长的眼睛停留时间的眼科组合物,特别是可以以滴剂形式施用的软膏形式的软膏剂等,其含有粘度增加的自由流动载体和防腐剂,并且在适当的情况下, 一种或多种活性成分和常规添加剂,例如张度剂,调节pH等的物质。防腐剂基本上由苄基月桂基二甲基铵盐形成。 本发明还涉及苄基月桂基二甲基铵盐作为防腐剂用于生产用于在长时间内重复使用的眼用组合物和/或在每次使用后配制成长时间在眼睛上停留时间的用途,由此对组织的刺激和/或损伤 避免眼睛。
    • 4. 发明授权
    • Process for producing a sterile prednisolone gel
    • 生产无菌泼尼松龙凝胶的方法
    • US5811417A
    • 1998-09-22
    • US696873
    • 1996-11-27
    • Gunther Bellmann
    • Gunther Bellmann
    • A61K9/06A61K9/00A61K31/57A61K31/573A61K47/32A61K31/56
    • A61K47/32A61K31/57A61K9/0014
    • The invention concerns a method for producing a sterile prednisolone gel. The method is characterized in that prednisolone or its pharmaceutically acceptable ester is sterilized and incorporated into a sterile polyacrylate gel, which has been per se conventionally produced, in appropriate amount under aseptic conditions, or else the sterile prednisolone or its pharmaceutically acceptable ester is suspended in a part of the amount of water required for producing the polyacrylate suspension and is then homogenously incorporated into the polyacryate, which is then made into a gel.
    • PCT No.PCT / EP95 / 00155 Sec。 371日期:1996年11月27日 102(e)日期1996年11月27日PCT提交1995年1月17日PCT公布。 WO95 / 22333 PCT出版物 日期1995年8月24日本发明涉及一种生产无菌泼尼松龙凝胶的方法。 该方法的特征在于将泼尼松龙或其药学上可接受的酯灭菌并掺入无菌聚丙烯酸酯凝胶中,该无菌聚丙烯酸酯凝胶在无菌条件下以适当的量在本来已经传统地制备,或者将无菌泼尼松龙或其药学上可接受的酯悬浮于 一部分生产聚丙烯酸酯悬浮液所需的水量,然后均匀地掺入聚丙烯酸酯中,然后将其制成凝胶。